摘要:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
摘要:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
摘要:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
摘要:
The present invention relates to the field of communications, and provides a communication method using spatial division multiple access (SDMA), to optimize an existing spatial division multiplexing mechanism. The method comprises: for each channel including a service channel and a control channel, according to a service information amount and/or a control information amount of the channel and a decision threshold corresponding to the channel, determining whether to activate SDMA for the channel; according to a decision result for a remote radio unit (RRU) to which each user belongs, allocating resources in an SDMA manner for the channel with the SDMA activated, and sending data of each user on the channel only on the RRU to which the user belongs; for a channel with the SDMA not activated, sending all data on the channel on all RRUs. The present invention is applicable to the spatial division multiplexing of various physical channels and physical signals specified by the standards of LTE and LTE-A systems, and can further improve utilization of resources in the system, the throughput of the system, and the data transmission rate.
摘要:
An injectable composition having dermal filling and tissue expanding activity comprises (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion, and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen, in other alternatives, the composition can further comprise hyaluronic acid, and one or more of the elastin, the collagen, and the hyaluronic acid, if present can be cross-linked, either intramolecularly or intermolecularly. The elastin, however, is the primary filler, even if collagen or hyaluronic acid are included in the composition
摘要:
In applications where data is transmitted in frames of symbols and the transmission medium is such that the probability of correct reception of symbols is, on the average, not uniform for different symbols in a frame, transmission of test frames enables creation of information about the different probabilities of correct reception, and that information is employed by the transmitter to control the manner in which symbols are transmitted so as to ameliorate the effects of the different probabilities of correct reception.
摘要:
The present invention discloses methods and compositions comprising a biocompatible gel that is used in tissue repair and regeneration. Once the gel is administered to a tissue site in need of repair or regeneration, the cells migrate from the gel into the tissue and repair or regenerate the tissue.
摘要:
The present invention relates to a compound of formula I wherein R1, R2, R3, R4, R7, m and n are as defined herein. These compounds are high potential NK-3 receptor antagonists useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要:
The present invention relates to a compound of formula I wherein R1, R2, R3, R4, R7, m and n are as defined herein.These compounds are high potential NK-3 receptor antagonists useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译:本发明涉及式Ⅰ化合物,其中R 1,R 2,R 3,R 4, R 7,m和n如本文所定义。 这些化合物是可用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。